Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

11C Lu AF90103

X
Drug Profile

11C Lu AF90103

Alternative Names: [11C]-Lu AF90103; Lu-AF90103

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Unspecified(Diagnosis, In the elderly, In volunteers, In adults) in Netherlands (IV, Infusion)
  • 23 Mar 2022 Phase-I clinical trials in Unspecified (Diagnosis, In volunteers, In adults) in Sweden (IV) (NCT05306366)
  • 26 May 2021 Phase-I clinical trials in Unspecified (Diagnosis, In volunteers, In adults, In the elderly) in Netherlands (IV) (NCT04940949)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top